Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial

Region Skane7 个研究点分布在 1 个国家目标入组 40 人开始时间: 2026年10月1日最近更新: 2026年6月24日

试验速览

To evaluate the effect of the intervention compared with control on self-rated breathlessness intensity after 60 minutes.

•Signed informed consent
•Aged 18 years or older
•Serious, chronic, life-limiting disease
•Short expected survival, defined as an no-answer to the ‘surprise question’: ‘Would you be surprised if the patient died within the next year?)[1], as judged by the trial staff
•Able to self-report symptoms
•Self-rated breathlessness at least 3/10 on ESAS-r breathlessness scale at rest

•Acute worsening of breathlessness that may be better relieved by disease-specific treatment
•Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of participation in the trial as judged by the Investigator.
•Contraindication for the intervention as judged by the Investigator, including allergy towards morphine, current or planned pregnancy.
•Treatment with methadone in any dose.
•Daily opioid dose (excluding the trial treatment) of > (more than) 160mg morphine equivalents, corresponding to more than 50 mikrogr fentanyl, 80 mg oxycodone per os, 60 mg oxycodone sc, or 16 mg hydromorphone sc during the last 24 hours.
•Received the randomized treatment as part of the trial within the previous 6 hours
•Received the randomized treatment in the trial 8 times already
•Participation or recent participation in a clinical trial with another investigational medicinal product within 30 days

发起方

申办方类型

Hospital/Clinic/Other health care facility

责任方

Principal Investigator

主要研究者

Magnus Ekström

Scientific

Region Skane

Loading locations...